Amarin Corp Plc (AMRN)

[redlyon]

Can anyone give statistical insight into the likelihood of an early halt to ReduceIt? Enough cardiovascular events in the statin control group would seem to be the driver--assuming of course that corresponding events in the V group will be significantly fewer. So if AMRN came close to its target of 50% enrollment at the end of 2012--lets assume 3800 enrolled 12/31/2012 and enrollment split equally between groups--that would give us 1900 control group patients who will log at least 2 years observation by the end of calendar 2014. How many of these statin-only patients would have likely experienced a qualifying cardiovascular "event"? If we can get a handle on this number and its progression in year 3, then we can move on to more rigorous P value discussions.